Small-molecule inhibitors targeting discoidin domain receptor 1 and uses thereof

US10370360B2 · kind B2 · utility

Assignees

• The Board of Regents of the University of Texas System · US
• Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences · CN

Inventors

• Rolf A. Brekken · Seattle, US
• Ke Ding · 流花街道, CN
• Xiaomei REN · Tangxia, CN
• Zhengchao Tu · 流花街道, CN
• Zhen Wang · 流花街道, CN
• Kristina Y. Aguilera · Dallas, US

Key dates

• Filing date: Oct 21, 2015
• Grant date: Aug 6, 2019
• Expiry date: Nov 20, 2035

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2300/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of formula (I), their pharmaceutically acceptable salts and stereoisomers thereof, as well as application in effectively inhibiting the enzymatic activity of discoidin domain receptor 1 and can be used as new therapeutic agents for preventing and treating e.g. inflammation, liver fibrosis, kidney fibrosis, lung fibrosis, skin scar, atherosclerosis, and cancer. The compound of formula I is: wherein the variables are as defined herein.